Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > "Market"? No invester shows in the last 2 years?
View:
Post by SouthernTierTom on May 02, 2022 10:47pm

"Market"? No invester shows in the last 2 years?

Maybe it is really good at the end of the day and people want as much as possible at 
the best possible price?

The science does indeed appear worthy of attention, but without a marketing strategy buying pressure will evade us

Feels like another UHN gem... Spectral Medical has 4 FDA approvals and a current phase 3B FDA confirmatory trial with a 2.10 cad SP target and an OTC listing here in the US with NO newsflow to America in the last 66 months... more UHN rooted science and heavy insider rooted ownership
Is this the same kind of story?

Time to get real here and cut the story telling bullbored bull

24 cents for a phase 2B FDA fast track for cancer?

yeah... keep chatting up that covey vax ; - )



Something doesnt add up here... a FDA fast track and a 50 mill market csp.. phase 2 Bellus worth 1.2 Billion for chronic cough remedy?  Hmmm??
Comment by SouthernTierTom on May 02, 2022 11:22pm
CONFUSED or impaired? ... Actually chum...I'm comparing TLT to T.BLU ..a phase 2 chronic cough player valued over 20 TIMES the value of TLT.. You might want to find out why we aren't "sharing our story" ..DO IT QUICK before the next raise.. JMHO.. Maybe it is really good at the end of the day and people want as much as possible at  the best possible price? The science ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250